Progenity, Inc.
8
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Small Intestinal Bacterial Overgrowth: A Prospective Registry
Role: collaborator
Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers
Role: lead
Whole Blood Specimen Collection From Healthy Subjects
Role: lead
Whole Blood Specimen Collection From Pregnant Subjects
Role: lead
Measuring Practice Pattern Changes and Clinical Utility of a Novel Test for Preeclampsia
Role: collaborator
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Role: lead
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Role: lead
Non-Invasive Screening for Fetal Aneuploidy
Role: lead
All 8 trials loaded